{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:51:21Z","timestamp":1793613081630,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-116"],"award-info":[{"award-number":["2022-PUMCH-B-116"]}]},{"name":"The National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-052"],"award-info":[{"award-number":["2022-PUMCH-B-052"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To determine the optimal planning target volume (PTV) margins for adequate coverage by daily iterative cone-beam computed tomography (iCBCT)-guided online adaptive radiotherapy (oART) in postoperative treatment of endometrial and cervical cancer and the benefit of reducing PTV margins.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifteen postoperative endometrial and cervical cancer patients treated with daily iCBCT-guided oART were enrolled in this prospective phase 2 study. Pre- and posttreatment iCBCT images of 125 fractions from 5 patients were obtained as a training cohort, and clinical target volumes (CTV) were contoured separately. Uniform three-dimensional expansions were applied to the PTVpre to assess the minimum margin required to encompass the CTVpost. The dosimetric advantages of the proposed online adaptive margins were compared with conventional margin plans (7\u201315\u00a0mm) using an oART emulator in another cohort of 125 iCBCT scans. A CTV-to-PTV expansion was verified on a validation cohort of 253 fractions from 10 patients, and further margin reduction and acute toxicity were studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The average time from pretreatment iCBCT to posttreatment iCBCT was 22\u00a0min. A uniform PTV margin of 5\u00a0mm could encompass nodal CTVpost in 100% of the fractions (175\/175) and vaginal CTVpost in 98% of the fractions (172\/175). The margin of 5\u00a0mm was verified in our validation cohort, and the nodal PTV margin could be further reduced to 4\u00a0mm if\u2009\u2265\u200995% CTV coverage was predicted to be achieved. The adapted plan with a 5\u00a0mm margin significantly improved pelvic organ-at-risk dosimetry compared with the conventional margin plan. Grade 3 toxicities were observed in only one patient with leukopenia, and no patients experienced acute urinary toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the postoperative treatment of endometrial and cervical cancer, oART could reduce PTV margins to 5\u00a0mm, which significantly decrease the dose to critical organs at risk and potentially lead to a lower incidence of acute toxicity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02394-2","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T16:01:38Z","timestamp":1704384098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Evaluation of PTV margins with daily iterative online adaptive radiotherapy for postoperative treatment of endometrial and cervical cancer: a prospective single-arm phase 2 study"],"prefix":"10.1186","volume":"19","author":[{"given":"Guangyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunFang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"9717","key":"2394_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s0140-6736(09)62163-2","volume":"6","author":"RA Nout","year":"2010","unstructured":"Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet Mar. 2010;6(9717):816\u201323. https:\/\/doi.org\/10.1016\/s0140-6736(09)62163-2","journal-title":"Lancet Mar"},{"issue":"6","key":"2394_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s11912-011-0191-y","volume":"13","author":"CL Creutzberg","year":"2011","unstructured":"Creutzberg CL, Nout RA. The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep Dec. 2011;13(6):472\u20138. https:\/\/doi.org\/10.1007\/s11912-011-0191-y","journal-title":"Curr Oncol Rep Dec"},{"key":"2394_CR3","doi-asserted-by":"publisher","first-page":"103704","DOI":"10.1016\/j.critrevonc.2022.103704","volume":"174","author":"E Perrucci","year":"2022","unstructured":"Perrucci E, Cerrotta A, Macchia G, et al. Postoperative treatment of intermediate-risk early stage cervical cancer: results of a survey from the gynecology study group in the AIRO Gyn and MITO groups. Crit Rev Oncol Hematol Jun. 2022;174:103704. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103704","journal-title":"Crit Rev Oncol Hematol Jun"},{"issue":"3","key":"2394_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/jamaoncol.2020.7168","volume":"1","author":"H Huang","year":"2021","unstructured":"Huang H, Feng YL, Wan T, et al. Effectiveness of sequential chemoradiation vs concurrent chemoradiation or radiation alone in adjuvant treatment after hysterectomy for cervical cancer: the STARS phase 3 randomized clinical trial. JAMA Oncol Mar. 2021;1(3):361\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7168","journal-title":"JAMA Oncol Mar"},{"issue":"9","key":"2394_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","volume":"119","author":"BG Wortman","year":"2018","unstructured":"Wortman BG, Creutzberg CL, Putter H, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer Oct. 2018;119(9):1067\u201374. https:\/\/doi.org\/10.1038\/s41416-018-0310-8","journal-title":"Br J Cancer Oct"},{"key":"2394_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13014-015-0495-4","volume":"17","author":"L Li","year":"2015","unstructured":"Li L, Kou X, Feng X, Zhang M, Chao H, Wang L. Postoperative external beam irradiation with and without brachytherapy in pelvic node-positive IB1-IIA2 cervical cancer patients: a retrospective clinical study. Radiat Oncol Sep. 2015;17:10:189. https:\/\/doi.org\/10.1186\/s13014-015-0495-4","journal-title":"Radiat Oncol Sep"},{"issue":"8","key":"2394_CR7","doi-asserted-by":"publisher","first-page":"e0183339","DOI":"10.1371\/journal.pone.0183339","volume":"12","author":"YK Kwak","year":"2017","unstructured":"Kwak YK, Lee SW, Kay CS, Park HH. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose. PLoS ONE. 2017;12(8):e0183339. https:\/\/doi.org\/10.1371\/journal.pone.0183339","journal-title":"PLoS ONE"},{"issue":"2","key":"2394_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.radonc.2009.08.042","volume":"93","author":"F Alongi","year":"2009","unstructured":"Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol Nov. 2009;93(2):207\u201312. https:\/\/doi.org\/10.1016\/j.radonc.2009.08.042","journal-title":"Radiother Oncol Nov"},{"issue":"2","key":"2394_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ijrobp.2007.09.042","volume":"1","author":"W Small Jr","year":"2008","unstructured":"Small W Jr., Mell LK, Anderson P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys Jun. 2008;1(2):428\u201334. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.09.042","journal-title":"Int J Radiat Oncol Biol Phys Jun"},{"issue":"2","key":"2394_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijrobp.2011.12.020","volume":"1","author":"K Vandecasteele","year":"2012","unstructured":"Vandecasteele K, Tummers P, Makar A, et al. Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity. Int J Radiat Oncol Biol Phys Oct. 2012;1(2):408\u201314. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.020","journal-title":"Int J Radiat Oncol Biol Phys Oct"},{"issue":"6","key":"2394_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/jjco\/hyab047","volume":"28","author":"G Zhang","year":"2021","unstructured":"Zhang G, He F, Miao L, Wu H, Zhang Y, Fu C. Post-operative small pelvic intensity-modulated radiation therapy for early-stage cervical cancer with intermediate-risk factors: efficacy and toxicity. Jpn J Clin Oncol May. 2021;28(6):905\u201310. https:\/\/doi.org\/10.1093\/jjco\/hyab047","journal-title":"Jpn J Clin Oncol May"},{"issue":"1","key":"2394_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13014-021-01866-7","volume":"23","author":"R de Jong","year":"2021","unstructured":"de Jong R, Visser J, van Wieringen N, Wiersma J, Geijsen D, Bel A. Feasibility of Conebeam CT-based online adaptive radiotherapy for neoadjuvant treatment of rectal cancer. Radiat Oncol Jul. 2021;23(1):136. https:\/\/doi.org\/10.1186\/s13014-021-01866-7","journal-title":"Radiat Oncol Jul"},{"key":"2394_CR13","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.ctro.2023.100596","volume":"40","author":"CE Shelley","year":"2023","unstructured":"Shelley CE, Bolt MA, Hollingdale R, et al. Implementing cone-beam computed tomography-guided online adaptive radiotherapy in cervical cancer. Clin Transl Radiat Oncol May. 2023;40:100596. https:\/\/doi.org\/10.1016\/j.ctro.2023.100596","journal-title":"Clin Transl Radiat Oncol May"},{"issue":"2","key":"2394_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ijrobp.2020.08.061","volume":"1","author":"W Small Jr","year":"2021","unstructured":"Small W Jr., Bosch WR, Harkenrider MM, et al. NRG Oncology\/RTOG Consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer: an update. Int J Radiat Oncol Biol Phys Feb. 2021;1(2):413\u201324. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.061","journal-title":"Int J Radiat Oncol Biol Phys Feb"},{"issue":"1","key":"2394_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijrobp.2008.10.086","volume":"1","author":"C Fiorino","year":"2009","unstructured":"Fiorino C, Alongi F, Perna L, et al. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys Sep. 2009;1(1):29\u201335. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.086","journal-title":"Int J Radiat Oncol Biol Phys Sep"},{"issue":"1","key":"2394_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mp.15365","volume":"49","author":"D Wang","year":"2022","unstructured":"Wang D, Yin Y, Zhou Q, et al. Dosimetric predictors and lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation. Med Phys Jan. 2022;49(1):756\u201367. https:\/\/doi.org\/10.1002\/mp.15365","journal-title":"Med Phys Jan"},{"issue":"24","key":"2394_CR17","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/jco.2017.77.4273","volume":"20","author":"AH Klopp","year":"2018","unstructured":"Klopp AH, Yeung AR, Deshmukh S, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203. J Clin Oncol Aug. 2018;20(24):2538\u201344. https:\/\/doi.org\/10.1200\/jco.2017.77.4273","journal-title":"J Clin Oncol Aug"},{"key":"2394_CR18","doi-asserted-by":"publisher","unstructured":"Morgan HE, Wang K, Yan Y, et al. Preliminary evaluation of PTV margins for online adaptive radiation therapy of the prostatic fossa. Pract Radiat Oncol Dec. 2022;10. https:\/\/doi.org\/10.1016\/j.prro.2022.11.003","DOI":"10.1016\/j.prro.2022.11.003"},{"issue":"2","key":"2394_CR19","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/j.prro.2022.10.009","volume":"13","author":"A Yen","year":"2023","unstructured":"Yen A, Choi B, Inam E, et al. Spare the bowel, don\u2019t spoil the target: optimal margin assessment for online cone beam adaptive radiation therapy (OnC-ART) of the cervix. Pract Radiat Oncol Mar-Apr. 2023;13(2):e176\u201383. https:\/\/doi.org\/10.1016\/j.prro.2022.10.009","journal-title":"Pract Radiat Oncol Mar-Apr"},{"issue":"1","key":"2394_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijrobp.2010.06.003","volume":"1","author":"N Tyagi","year":"2011","unstructured":"Tyagi N, Lewis JH, Yashar CM, et al. Daily online cone beam computed tomography to assess interfractional motion in patients with intact cervical cancer. Int J Radiat Oncol Biol Phys May. 2011;1(1):273\u201380. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.003","journal-title":"Int J Radiat Oncol Biol Phys May"},{"issue":"1","key":"2394_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ijrobp.2010.08.024","volume":"1","author":"A Jhingran","year":"2012","unstructured":"Jhingran A, Salehpour M, Sam M, Levy L, Eifel PJ. Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy. Int J Radiat Oncol Biol Phys Jan. 2012;1(1):256\u201362. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.024","journal-title":"Int J Radiat Oncol Biol Phys Jan"},{"issue":"2","key":"2394_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.radonc.2010.10.026","volume":"98","author":"IM J\u00fcrgenliemk-Schulz","year":"2011","unstructured":"J\u00fcrgenliemk-Schulz IM, Toet-Bosma MZ, de Kort GA, et al. Internal motion of the vagina after hysterectomy for gynaecological cancer. Radiother Oncol Feb. 2011;98(2):244\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2010.10.026","journal-title":"Radiother Oncol Feb"},{"issue":"2","key":"2394_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.radonc.2012.08.012","volume":"105","author":"LV Laursen","year":"2012","unstructured":"Laursen LV, Elstr\u00f8m UV, Vestergaard A, et al. Residual rotational set-up errors after daily cone-beam CT image guided radiotherapy of locally advanced cervical cancer. Radiother Oncol Nov. 2012;105(2):220\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2012.08.012","journal-title":"Radiother Oncol Nov"},{"key":"2394_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2022.09.015","volume":"176","author":"LM \u00c5str\u00f6m","year":"2022","unstructured":"\u00c5str\u00f6m LM, Behrens CP, Storm KS, Sibolt P, Serup-Hansen E. Online adaptive radiotherapy of anal cancer: normal tissue sparing, target propagation methods, and first clinical experience. Radiother Oncol Nov. 2022;176:92\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2022.09.015","journal-title":"Radiother Oncol Nov"},{"key":"2394_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.radonc.2022.01.013","volume":"168","author":"A Al-Mamgani","year":"2022","unstructured":"Al-Mamgani A, Kessels R, Janssen T, et al. The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6\u00a0mm in head and neck squamous cell carcinoma: significant acute and late toxicity reduction. Radiother Oncol Mar. 2022;168:16\u201322. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.013","journal-title":"Radiother Oncol Mar"},{"issue":"5","key":"2394_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.ijrobp.2010.04.041","volume":"1","author":"MD Hasselle","year":"2011","unstructured":"Hasselle MD, Rose BS, Kochanski JD, et al. Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys Aug. 2011;1(5):1436\u201345. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.04.041","journal-title":"Int J Radiat Oncol Biol Phys Aug"},{"issue":"9","key":"2394_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1159\/000476037","volume":"40","author":"S Yuce Sari","year":"2017","unstructured":"Yuce Sari S, Guler OC, Gultekin M, Onal HC, Yildiz F. Adjuvant small pelvic radiotherapy in patients with cervical cancer having intermediate risk factors only - is it sufficient? Oncol Res Treat. 2017;40(9):523\u20137. https:\/\/doi.org\/10.1159\/000476037","journal-title":"Oncol Res Treat"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02394-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T04:42:15Z","timestamp":1704429735000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02394-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2394"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02394-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Institutional Review Board of Peking Union Medical College Hospital (No. K2416).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}